GELS
Gelteq Limited Ordinary SharesGELS
GELS
About: Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels.
Employees: 8
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
67% more funds holding
Funds holding: 3 [Q4 2024] → 5 (+2) [Q1 2025]
0.26% more ownership
Funds ownership: 0.86% [Q4 2024] → 1.11% (+0.26%) [Q1 2025]
43% less capital invested
Capital invested by funds: $187K [Q4 2024] → $108K (-$79.9K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for GELS.
Financial journalist opinion
Neutral
GlobeNewsWire
5 days ago
Gelteq Expands U.S. Operations with Healthy Extracts Inc. as North American Fulfillment Partner
Major commercial expansion of its U.S. strategy through logistics and distribution agreement Major commercial expansion of its U.S. strategy through logistics and distribution agreement
Neutral
GlobeNewsWire
3 months ago
Gelteq's Sportsgel Brand Named Official Sponsor of the Professional Pickleball Tour and League of Australia and New Zealand
Sportsgel signs first league-wide sports deal to be the official performance gel of the preeminent pickleball tour across the Oceania region Sportsgel signs first league-wide sports deal to be the official performance gel of the preeminent pickleball tour across the Oceania region
Neutral
GlobeNewsWire
4 months ago
Gelteq Appoints Matthew Jones as Head of Sports Performance
Leading internationally-experienced sports nutritionist joins the Company's growing team to expand its sports vertical Leading internationally-experienced sports nutritionist joins the Company's growing team to expand its sports vertical
Neutral
GlobeNewsWire
5 months ago
Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug
Approval grants Gelteq fast track pathway for drug and entrance into the animal pharmaceuticals space Approval grants Gelteq fast track pathway for drug and entrance into the animal pharmaceuticals space
Neutral
GlobeNewsWire
6 months ago
Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces that its Co-Founders, CEO Mr. Nathan Givoni and Executive Chairman Mr. Simon Szewach, will be participating in the Benchmark Company 13th Annual Discovery Investor Conference being held on Wednesday, December 11, 2024, at the New York Athletic Club in New York City.
Neutral
GlobeNewsWire
6 months ago
Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand
Healthy Extracts expands order after high demand for Gelteq's collagen and Mynus sugar blocker gels Healthy Extracts expands order after high demand for Gelteq's collagen and Mynus sugar blocker gels
Neutral
GlobeNewsWire
6 months ago
Gelteq Announces 400,000 Units Enter into Production in November 2024
NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products, announces today that in November, 400,000 units of its gel solution are entering into production. These units will fulfill orders made for clients in the U.S and Australia. Delivery is expected in January 2025 for sales across the two countries as well as in the UAE and in Asia. The production run includes Gelteq nutraceutical products in the areas of sports, anti-aging, and weight loss.
Neutral
GlobeNewsWire
7 months ago
Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, announced today that it has expanded its operations in the United States with the appointment of Adam Bendell as President of U.S. Operations.
Neutral
GlobeNewsWire
7 months ago
Gelteq Limited Closes US$5.2 Million Initial Public Offering
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a global biotechnology company that specializes in the formulation, development, and manufacturing of ingestible gel technology, announced today the closing of its initial public offering of 1,300,000 ordinary shares at a public offering price of US$4.00 per share. The ordinary shares commenced trading on the Nasdaq Global Market on October 29, 2024 under the symbol “GELS.”
Neutral
GlobeNewsWire
7 months ago
Gelteq Limited Prices US$5.2 Million Initial Public Offering
Company anticipates commencement of trading on Nasdaq effective October 29, 2024 under the symbol “GELS” Company anticipates commencement of trading on Nasdaq effective October 29, 2024 under the symbol “GELS”
Charts implemented using Lightweight Charts™